NCT01231685: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection |
|
|
| Completed | 2 | 9 | Canada | Raltegravir, Isentress, MK-0518, RGV, Ritonavir-boosted protease inhibitor, Kaletra, Lopinavir-ritonavir, Atazanavir-ritonavir, Reyataz-norvir, Darunavir-ritonavir, Presista-norvir | McGill University Health Centre/Research Institute of the McGill University Health Centre, Merck Sharp & Dohme LLC, CIHR Canadian HIV Trials Network | HIV, Hepatitis C, Liver Fibrosis | 03/16 | 09/16 | | |
